Immutep Ltd: Maxim Group raises to buy from hold

Maxim Group has upgraded its rating for Immutep Ltd (IMMP) from "Hold" to "Buy," citing positive developments related to the company's key catalysts and valuation trends. The move reflects the firm's confidence in Immutep's progress in its LAG-3 immunotherapy programs and stabilization of the biotech sector. Analysts highlight the company's strong partnerships with major pharmaceutical firms, including Merck and Pfizer, as a key factor in capture market share.

Despite the upgraded rating, the broader analyst consensus for Immutep remains "Hold," with two analysts recommending a "Buy" and two suggesting a "Hold," while no analysts recommend a "Strong Buy" or "Sell." The current price target set by analysts is $5.50, indicating no change from current stock price.

Investors are advised to consider both the company's promising pipeline and the competitive landscape, as clinical trial outcomes and market dynamics could influence future performance.